Stay updated with breaking news from Brianm Strem. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Kiora Pharmaceuticals, Inc. today announced its 2023 financial results and provided an update on its retinal disease development pipeline. The Company's major initiatives planned for 2024 are to...
Encinitas, California--(Newsfile Corp. - April 27, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) presented preliminary results from an ongoing clinical trial showing its investigational drug, KIO-301,
In a second presentation, Kiora shared additional positive results for its KIO-100 platform in the treatment of autoimmune uveitis. Encinitas, California--(Newsfile Corp. - April 26, 2023) - Kiora Pharmaceuticals
Encinitas, California--(Newsfile Corp. - April 21, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed Mark Pennesi, M.D., Ph.D., the Kenneth C. Swan Endowed Professor in Ophthalmology and Molecular
Putting Australian clinical research on the map globally, comes the ground-breaking first-in-human clinical trial for KIO-301. MELBOURNE, Australia, Feb. 15, 2023 /PRNewswire/ -- In collaboration with US-based Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) and The Royal Adelaide Hospital, leading Australian CRO, Accelagen, is proud to announce that dosing has commenced in the Phase 1 first-in-human trial for KIO-301. This trial represents a remarkable development in the treatment of people with the rare inherited condition, Retinitis Pigmentosa (RP), which currently has no approved cure or standar...